Matches in Nanopublications for { ?s ?p "DDI between Zolmitriptan and Tranylcypromine - The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated. [drugbank_resource:DB00315_DB00752]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00315_DB00752 label "DDI between Zolmitriptan and Tranylcypromine - The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated. [drugbank_resource:DB00315_DB00752]" assertion.